Amarin Corporation plc announced that on June 1, 2022, Michael W. Kalb, company's Senior Vice President notified the company that he would be resigning from the company, and on June 6, 2022, Amarin announced the appointment of Tom Reilly as company's new Senior Vice President as successor to Mr. Kalb, effective June 20, 2022 (or such earlier date as may be agreed with the Company, the “ CFO Appointment Date”). Mr. Kalb is leaving the company to pursue other interests after transitioning the role to Mr. Reilly. Mr. Reilly, age 50, has more than 20 years of experience in building and leading finance and administration teams at life sciences companies both in the United States and globally.

Most recently Mr. Reilly served as chief financial officer for Cara Therapeutics Inc. (“ Cara”), where he was responsible for leading all aspects of the Cara's financial operations and planning. Prior to Cara, Mr. Reilly served as head of finance of the Allergan General Medicines business. Prior to joining Allergan, Mr. Reilly spent 14 years with Novartis where he served in roles of increasing responsibility, including finance head for Novartis' Oncology Development unit, as chief financial officer for Novartis Pharma Austria and financial controller for Novartis USA's Pharmaceutical Division.

He earned his bachelor's degree in finance from Manhattan College, an M.B. A in accounting from Seton Hall University and is a certified public accountant.